

# Stephen D Ryder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2226657/publications.pdf>

Version: 2024-02-01

99  
papers

8,538  
citations

126907

33  
h-index

49909

87  
g-index

100  
all docs

100  
docs citations

100  
times ranked

9835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
3	Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2008, 135, 1176-1184.	1.3	636
4	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2015, 372, 1619-1628.	27.0	602
5	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	13.7	492
6	Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. <i>Journal of Hepatology</i> , 2001, 35, 195-199.	3.7	300
7	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
8	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
9	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
10	Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. <i>Journal of Hepatology</i> , 2000, 33, 371-375.	3.7	197
11	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 808-817.	27.0	181
12	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, 533-540.	3.7	161
13	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
14	In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. <i>Gastroenterology</i> , 2017, 152, 1068-1077.e4.	1.3	141
15	Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. <i>British Journal of Cancer</i> , 2008, 98, 1166-1175.	6.4	121
16	Directex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. <i>European Journal of Immunology</i> , 2001, 31, 2388-2394.	2.9	118
17	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	7.3	103
18	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
20	Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 685-686.	3.7	88
21	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. <i>BMJ Open</i> , 2015, 5, e007516-e007516.	1.9	86
22	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet</i> , The, 2015, 386, 2098-2111.	13.7	76
23	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	3.9	76
24	Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 511-518.	3.7	73
25	Mannan binding lectin and viral hepatitis. <i>Immunology Letters</i> , 2007, 108, 34-44.	2.5	62
26	Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 262.	1.6	62
27	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1170-1178.e6.	4.4	61
28	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. <i>Journal of Clinical Pathology</i> , 2010, 63, 790-795.	2.0	51
29	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 504-515.	3.7	49
30	Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 442-453.	3.7	48
31	The natural history of hepatitis C with severe hepatic fibrosis. <i>Journal of Hepatology</i> , 2007, 47, 37-45.	3.7	45
32	Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 171-180.	0.5	41
33	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	5.8	35
34	NLA0801, an anti-chemokine (CX3C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 492-503.	4.3	35
35	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 951-960.	3.7	34
36	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. <i>Health Technology Assessment</i> , 2015, 19, 1-104. <sup>2.8</sup>		34

#	ARTICLE	IF	CITATIONS
37	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2017, 389, 2053-2080.	13.7	33
38	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. <i>Addiction</i> , 2019, 114, 1113-1122.	3.3	33
39	Glecaprevir/Pibrentasvir in patients with chronic <scp>HCV</scp> genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 337-349.	2.0	32
40	Screening for hepatocellular carcinoma: patient selection and perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 71-79.	3.7	27
41	The impact of rifaximin-± on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). <i>Frontline Gastroenterology</i> , 2017, 8, 243-251.	1.8	26
42	The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis: Whose Score Is It Anyway?. <i>International Journal of Hepatology</i> , 2012, 2012, 1-5.	1.1	24
43	Health outcomes following liver function testing in primary care: a retrospective cohort study. <i>Family Practice</i> , 2009, 26, 251-259.	1.9	23
44	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	7.3	22
45	Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis. <i>Alcohol and Alcoholism</i> , 2021, 56, 185-200.	1.6	22
46	Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 1200-1201.	3.7	21
47	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , 2021, 41, 934-948.	3.9	18
48	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2021, 397, 1770-1780.	13.7	18
49	The hepatitis C revolution part 1. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 563-571.	3.1	17
50	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. <i>European Journal of Health Economics</i> , 2021, 22, 505-518.	2.8	16
51	Will the COVID-19 pandemic affect HCV disease burden?. <i>Digestive and Liver Disease</i> , 2020, 52, 947-949.	0.9	15
52	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 201-207.	1.6	14
53	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <i>Journal of Medical Virology</i> , 2020, 92, 3403-3411.	5.0	14
54	Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. <i>Abnormal Liver Function Investigations Evaluation (ALFIE)</i> . <i>BMC Health Services Research</i> , 2007, 7, 54.	2.2	13

#	ARTICLE	IF	CITATIONS
55	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 186-194.	0.9	13
56	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 17-29.	0.9	12
57	Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes. <i>Journal of Viral Hepatitis</i> , 2021, 28, 420-430.	2.0	12
58	Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial. <i>American Journal of Gastroenterology</i> , 2021, 116, 2292-2295.	0.4	12
59	The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). <i>PLoS ONE</i> , 2012, 7, e50965.	2.5	12
60	Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. <i>European Radiology</i> , 2019, 29, 3100-3107.	4.5	11
61	Magnetic resonance cholangiopancreatography versus endoscopic retrograde cholangiopancreatography in the diagnosis of choledocholithiasis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 809-813.	1.6	11
62	Outcome of hepatitis C infection: Bleak or benign?. <i>Journal of Hepatology</i> , 2007, 47, 4-6.	3.7	10
63	&lt;p&gt;Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population&lt;/p&gt;. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 47-67.	2.5	10
64	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 500-512.	3.7	9
65	Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 123-130.	3.7	8
66	The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. <i>Alcohol and Alcoholism</i> , 2022, 57, 203-210.	1.6	8
67	The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?. <i>Liver International</i> , 2013, 33, 172-179.	3.9	7
68	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	7
69	Randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 543-550.	1.6	6
70	ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established. <i>American Journal of Gastroenterology</i> , 2019, 114, 175-176.	0.4	6
71	Engagement with community liver disease management across the UK: a cross-sectional survey. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0085.	1.8	6
72	Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e054954.	1.9	6

#	ARTICLE	IF	CITATIONS
73	Chronic hepatitis C “ what do the new drugs offer and who should get them first?. Clinical Medicine, 2015, 15, 197-200.	1.9	5
74	Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home. Clinical Medicine, 2021, 21, e32-e38.	1.9	4
75	Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. Biomedicines, 2022, 10, 477.	3.2	4
76	Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Thrombosis Research, 2022, 215, 19-29.	1.7	4
77	Alcohol-related liver disease mortality and missed opportunities in secondary care: A United Kingdom retrospective observational study. Drug and Alcohol Review, 2022, 41, 1331-1340.	2.1	4
78	Do high lipids help clearance of hepatitis C?. Gut, 2007, 56, 1044-1045.	12.1	3
79	Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan). Gastrointestinal Nursing, 2018, 16, S15-S22.	0.1	3
80	How to interpret and manage abnormal liver blood test results in older people. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-8.	0.5	3
81	Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis. PLoS ONE, 2022, 17, e0268034.	2.5	3
82	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. EBioMedicine, 2022, 80, 104068.	6.1	3
83	Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?. Frontline Gastroenterology, 2012, 3, 66-71.	1.8	2
84	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. Scientific Reports, 2021, 11, 21286.	3.3	2
85	IDDF2018-ABS-0107“...Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1
86	Commentary: elastography as a predictor of portal hypertension. Alimentary Pharmacology and Therapeutics, 2020, 51, 204-205.	3.7	1
87	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research, 2021, 6, 93.	1.8	1
88	Alcohol-related liver disease. Practitioner, 2003, 247, 414-7.	0.3	1
89	The Effect of Lectins on Crypt Cell Proliferation in Organ Culture. , 1998, 9, 475-482.		0
90	Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease. European Journal of Gastroenterology and Hepatology, 2006, 18, 343-347.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Hepatitis B virus part 2: treatment options and the role of the specialist nurse. <i>Gastrointestinal Nursing</i> , 2013, 11, 33-40.	0.1	0
92	The hepatitis C revolution part 2. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 572-575.	3.1	0
93	Reply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode". <i>Journal of Hepatology</i> , 2018, 68, 1332.	3.7	0
94	FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e398.	3.7	0
95	PTU-009...Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers. , 2019, , .		0
96	ATU-09...Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
97	Home based care pathway for the stratified treatment of HCV infection. <i>Journal of Hepatology</i> , 2020, 73, S22-S23.	3.7	0
98	Reply to Smith <i>et al.</i> Regarding "Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review with Meta-Analysis". <i>Alcohol and Alcoholism</i> , 2021, 56, 626-627.	1.6	0
99	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-90.	0.7	0